Downregulation of connective tissue growth factor reduces migration and invasiveness of osteosarcoma cells

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Osteosarcoma (OSA) is a primary bone tumor characterized by metastasis and chemotherapy resistance, leading to poor patient prognosis.
• Connective tissue growth factor (CTGF), a member of the CCN family, is implicated in cellular processes relevant to OSA.
• Understanding CTGF's role may reveal new therapeutic targets for overcoming OSA treatment failures.

Purpose of the Study:

• To investigate the role of CTGF in osteosarcoma (OSA) cell behavior, including proliferation, apoptosis, migration, and invasion.
• To evaluate the potential of CTGF as a therapeutic target for metastatic OSA.
• To determine if modulating CTGF affects the efficacy of chemotherapeutic drugs in OSA.

Main Methods:

• Small interfering RNA (siRNA) was used to silence CTGF expression in OSA cells.
• Lentivirus-mediated gene delivery was employed for CTGF overexpression.
• Cell apoptosis was assessed using acridine orange/ethidium bromide staining.
• Cell migration and invasion were evaluated through wound healing and Transwell assays.
• Caspase activity was measured using a colorimetric assay to assess drug efficacy.

Main Results:

• CTGF silencing significantly promoted cell death and suppressed OSA cell migration and invasion.
• Overexpression of CTGF reversed the effects observed upon silencing.
• Knockdown of CTGF enhanced the efficacy of standard chemotherapeutic drugs.
• These findings identify CTGF as a key regulator of OSA progression and chemosensitivity.

Conclusions:

• CTGF plays a crucial role in promoting osteosarcoma cell survival, migration, and invasion.
• Silencing CTGF presents a promising strategy to inhibit OSA progression and metastasis.
• Targeting CTGF may enhance the effectiveness of chemotherapy, offering a novel therapeutic approach for metastatic osteosarcoma.